Development Pipeline

In-house discovered and In-licensed projects(As of May 12, 2025)

Development Code Planned Indication Development Stage Remarks
KAR Head lice Phase Ⅲ In-licensed from Arbor Pharmaceuticals, LLC.
Product name in the US: Sklice
KP-001 Refractory vascular malformations Phase Ⅲ In-house discovered product
KC-8025 (Seladelpar) Primary biliary cholangitis Phase Ⅲ In-licensed from CymaBay Therapeutics, Inc.
Acquired by Gilead Sciences in February 2024.
ESK-001 Plaque psoriasis Phase Ⅲ In-licensed from Alumis Inc.
Under global Phase Ⅲ (incl. Japan)
KP-483 Solid tumors
(immuno-oncology)
Phase Ⅰ In-house discovered product
KP-910 Peripheral neuropathic pain Phase Ⅰ In-house discovered product
Tildacerfont Congenital adrenal hyperplasia Phase Ⅰ In-licensed from Spruce Biosciences, Inc.
KP-001(USA) Refractory vascular malformations Phase Ⅰ In-house discovered product
Consulting with FDA on Phase Ⅲ plan

Note:Kaken will advance KP-723, an oral STAT6 inhibitor in preclinical development, to the completion of Phase Ⅰ clinical trials, which had entered into a licence agreement with J&J.

Other(As of May 12, 2025)

Development Code Planned Indication Development Stage Remarks
Sebetralstat Hereditary Angioedema Authorization application Applied by KalVista Pharmaceuticals
NM-26 Atopic dermatitis Phase Ⅱ Clinical trial underway after IP transfer to J&J

Note:The medical device "Silk-Elastin Wound Healing Sheet", for which a marketing authorization application had been submitted by the licensor, Sanyo Chemical Industries, Ltd., was approved on April 21, 2025.

Status of Out-Licensed Products Overseas
(As of May 12, 2025)

Generic name
(domestic sales name)
Planned Indication Development Stage Out-licensed(Developing country)
Efinaconazole
(Clenafin)
Onychomycosis Authorization application Almirall S.A.(Germany ※Italy:Approved Mar 2025)
Efinaconazole
(Clenafin)
Onychomycosis Phase Ⅲ AIM(China)
Sofpironium bromide
(Ecclock)
Primary axillary hyperhidrosis Authorization application Dong-Wha Pharm Co., Ltd.(Korea)
PAGE TOP